ARPI Regimens Extended Prostate Cancer Progression-Free Survival
For men with metastatic prostate cancer, specific hormone therapies delayed disease progression longer than chemotherapy.
Updated on Oct. 6, 2026 in Cancer
Live Poll
Do you trust that real-world medical data helps patients choose the most effective treatment options?
A retrospective study of 9,141 men in the United States found that androgen receptor pathway inhibitors (ARPIs) combined with androgen deprivation therapy (ADT) delayed cancer progression compared to docetaxel plus ADT. This analysis, which concluded its follow-up in June 2025, highlights differences in treatment outcomes for patients managing metastatic hormone-sensitive prostate cancer.
Why it matters
Understanding which treatment regimens are most effective at delaying disease progression is vital for men managing metastatic prostate cancer. These findings provide clarity on the comparative performance of various standard-of-care therapies in real-world clinical settings.
This retrospective analysis used U.S. claims data to evaluate 9,141 men with metastatic hormone-sensitive prostate cancer, comparing the median progression-free survival of four different treatment regimens. While ARPI doublets consistently delayed disease progression compared to docetaxel, researchers noted no significant differences in overall survival between the groups.
The players
Komodo Healthcare Map
A comprehensive database used to analyze U.S. clinical claims and patient outcomes.
The details
Researchers utilized the Komodo Healthcare Map database and Cox proportional hazard models to assess patient outcomes between January 2019 and December 2023. By applying overlapping propensity score weights, the team compared androgen receptor pathway inhibitors—such as abiraterone, apalutamide, and enzalutamide—against the chemotherapy agent docetaxel when used alongside androgen deprivation therapy. The ARPI-based doublets successfully reduced the risk of progression to metastatic castration-resistant prostate cancer and delayed the need for subsequent treatments.
Timeline
Patients initiated their treatment regimens between January 2019 and December 2023.
The clinical follow-up period for this study concluded in June 2025.
Health Landscape
This research builds upon the established clinical standard for metastatic hormone-sensitive prostate cancer treatment in the United States. It provides a real-world assessment of how contemporary ARPI therapies compare to traditional chemotherapy approaches in patient populations.
Patients and caregivers should discuss these findings with their oncologists to understand how different hormone-based therapies compare for their specific clinical profile. It is worth asking your physician about the expected timeline for treatment progression and which therapeutic regimens align best with your long-term health goals.
The takeaway
While ARPI-based doublets showed longer progression-free survival than docetaxel, overall survival rates remained consistent across all four regimens studied. Patients should maintain regular checkups with their oncology team to monitor for signs of disease progression and discuss necessary adjustments to their care plan.
Further reading
For more information on managing advanced conditions, visit the Cancer section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that real-world medical data helps patients choose the most effective treatment options?
